Conditional Mesenchymal Disruption of Pkd1 Results in Osteopenia and Polycystic Kidney Disease

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Qiu, Ni ^a,b   Xiao, Zhousheng ^a   Cao, Li ^a   David, Valentin ^a   da Quarles, Leighrryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCYSTIN 1;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MARROW; CELL PROLIFERATION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DOSE RESPONSE; EX VIVO STUDY; FEMALE; GENE ACTIVITY; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETIC ASSOCIATION; KIDNEY POLYCYSTIC DISEASE; MALE; MESENCHYMAL STROMA CELL; MOLECULAR PATHOLOGY; MOUSE; NEWBORN; NONHUMAN; OSTEOPENIA; PANCREAS CYST; PKD1 GENE;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE DISEASES, METABOLIC; COLLAGEN TYPE I; EMBRYO, MAMMALIAN; GENE DELETION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; INTEGRASES; KIDNEY; MESODERM; MICE; OSTEOBLASTS; OSTEOGENESIS; PANCREAS; POLYCYSTIC KIDNEY DISEASES; TRPP CATION CHANNELS;

MUS;

EID: 84866682070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046038     Document Type: Article

References (74)

1. Xu H, Shen J, Walker CL, Kleymenova E, (2001) Tissue-specific expression and splicing of the rat polycystic kidney disease 1 gene. DNA Seq 12: 361-366.
2. Chauvet V, Qian F, Boute N, Cai Y, Phakdeekitacharoen B, et al. (2002) Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol 160: 973-983.
3. Gabow PA, (1993) Autosomal dominant polycystic kidney disease. N Engl J Med 329: 332-342.
4. Wilson PD, (2004) Polycystic kidney disease. N Engl J Med 350: 151-164.
5. Housset C, (2005) [Cystic liver diseases. Genetics and cell biology]. Gastroenterol Clin Biol 29: 861-869.
6. Skala I, Prat V, Mareckova O, Dite P, Vitek J, et al. (1985) [Cysts in the liver and pancreas in polycystic kidney in adults]. Vnitr Lek 31: 677-681.
7. Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, et al. (1997) Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 17: 179-181.
8. Schievink WI, Torres VE, Piepgras DG, Wiebers DO, (1992) Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3: 88-95.
9. Chauveau D, Pirson Y, Verellen-Dumoulin C, Macnicol A, Gonzalo A, et al. (1994) Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int 45: 1140-1146.
10. Peczkowska M, Januszewicz A, Grzeszczak W, Moczulski D, Janaszek-Sitkowska H, et al. (2004) The coexistence of acute aortic dissection with autosomal dominant polycystic kidney disease-description of two hypertensive patients. Blood Press 13: 283-286.
11. Hassane S, Claij N, Lantinga-van Leeuwen IS, Van Munsteren JC, Van Lent N, et al. (2007) Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model. Arterioscler Thromb Vasc Biol 27: 2177-2183.
12. Driscoll JA, Bhalla S, Liapis H, Ibricevic A, Brody SL, (2008) Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis. Chest 133: 1181-1188.
13. Garcia-Gonzalez MA, Outeda P, Zhou Q, Zhou F, Menezes LF, et al. (2010) Pkd1 and Pkd2 are required for normal placental development. PLoS One 5.
14. Lu W, Shen X, Pavlova A, Lakkis M, Ward CJ, et al. (2001) Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects. Hum Mol Genet 10: 2385-2396.
15. Boulter C, Mulroy S, Webb S, Fleming S, Brindle K, et al. (2001) Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci U S A 98: 12174-12179.
16. Xiao Z, Zhang S, Mahlios J, Zhou G, Magenheimer BS, et al. (2006) Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression. J Biol Chem 281: 30884-30895.
17. Xiao Z, Zhang S, Cao L, Qiu N, David V, et al. (2010) Conditional disruption of Pkd1 in osteoblasts results in osteopenia due to direct impairment of bone formation. J Biol Chem 285: 1177-1187.
18. Xiao Z, Dallas M, Qiu N, Nicolella D, Cao L, et al. (2011) Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J 25: 2418-2432.
19. Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, et al. (2011) Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 79: 234-240.
20. Brasier JL, Henske EP, (1997) Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. J Clin Invest 99: 194-199.
21. Pei Y, Watnick T, He N, Wang K, Liang Y, et al. (1999) Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10: 1524-1529.
22. Qian F, Watnick TJ, Onuchic LF, Germino GG, (1996) The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell. 87: 979-987.
23. Wu G, D'Agati V, Cai Y, Markowitz G, Park JH, et al. (1998) Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93: 177-188.
24. Gallagher AR, Germino GG, Somlo S, (2010) Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17: 118-130.
25. Piontek KB, Huso DL, Grinberg A, Liu L, Bedja D, et al. (2004) A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol 15: 3035-3043.
26. Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG, (2007) A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 13: 1490-1495.
27. Leuenroth SJ, Bencivenga N, Igarashi P, Somlo S, Crews CM, (2008) Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 19: 1659-1662.
28. Shillingford JM, Piontek KB, Germino GG, Weimbs T, (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21: 489-497.
29. Zha L, Hou N, Wang J, Yang G, Gao Y, et al. (2008) Collagen1alpha1 promoter drives the expression of Cre recombinase in osteoblasts of transgenic mice. J Genet Genomics 35: 525-530.
30. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, et al. (2006) Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172: 909-921.
31. Liu F, Woitge HW, Braut A, Kronenberg MS, Lichtler AC, et al. (2004) Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol 48: 645-653.
32. Dvorak-Ewell MM, Chen TH, Liang N, Garvey C, Liu B, et al. (2011) Osteoblast extracellular Ca2+-sensing receptor regulates bone development, mineralization, and turnover. J Bone Miner Res 26: 2935-2947.
33. Kwan KM, (2002) Conditional alleles in mice: practical considerations for tissue-specific knockouts. Genesis 32: 49-62.
34. Xiao ZS, Hjelmeland AB, Quarles LD, (2004) Selective deficiency of the "bone-related" Runx2-II unexpectedly preserves osteoblast-mediated skeletogenesis. J Biol Chem 279: 20307-20313.
35. Deal C, (2009) Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 21: 380-385.
36. Xiao Z, Zhang S, Magenheimer BS, Luo J, Quarles LD, (2008) Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. J Biol Chem 283: 12624-12634.
37. Caplan AI, (1991) Mesenchymal stem cells. J Orthop Res 9: 641-650.
38. Horster M, Huber S, Tschop J, Dittrich G, Braun G, (1997) Epithelial nephrogenesis. Pflugers Arch 434: 647-660.
39. Ahlgren U, Jonsson J, Edlund H, (1996) The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. Development 122: 1409-1416.
40. Zong Y, Stanger BZ, (2011) Molecular mechanisms of bile duct development. Int J Biochem Cell Biol 43: 257-264.
41. Yamaguchi T, Reif GA, Calvet JP, Wallace DP, (2010) Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol 299: F944-951.
42. Aguiari G, Bizzarri F, Bonon A, Mangolini A, Magri E, et al. (2012) Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation. J Mol Med (Berl).
43. Zhang S, Xiao Z, Luo J, He N, Mahlios J, et al. (2009) Dose-dependent effects of Runx2 on bone development. J Bone Miner Res 24: 1889-1904.
44. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, et al. (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108: 17-29.
45. Hou B, Kolpakova-Hart E, Fukai N, Wu K, Olsen BR, (2009) The polycystic kidney disease 1 (Pkd1) gene is required for the responses of osteochondroprogenitor cells to midpalatal suture expansion in mice. Bone 44: 1121-1133.
46. Jacob AL, Smith C, Partanen J, Ornitz DM, (2006) Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Dev Biol 296: 315-328.
47. Owen M (1988) Marrow stromal stem cells. J Cell Sci Suppl 10: 63-76.
48. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
49. Rickard DJ, Kassem M, Hefferan TE, Sarkar G, Spelsberg TC, et al. (1996) Isolation and characterization of osteoblast precursor cells from human bone marrow. J Bone Miner Res 11: 312-324.
50. Martin A DV, Li H, Dai B, Feng JQ, Quarles LD (2012) Overexpression of the DMP1 C-terminal Fragment Stimulates FGF23 and Exacerbates the Hypophosphatemic Rickets Phenotype in Hyp Mice. Mol Endocrinol: In press.
51. Guillaume R, D'Agati V, Daoust M, Trudel M, (1999) Murine Pkd1 is a developmentally regulated gene from morula to adulthood: role in tissue condensation and patterning. Dev Dyn 214: 337-348.
52. Torres VE, Harris PC, Pirson Y, (2007) Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301.
53. van Gulick JJ, Gevers TJ, van Keimpema L, Drenth JP, (2011) Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum. Neth J Med 69: 367-371.
54. Pirson Y, (2010) Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17: 173-180.
55. Kaehny WD, Everson GT, (1991) Extrarenal manifestations of autosomal dominant polycystic kidney disease. Semin Nephrol 11: 661-670.
56. Chauveau D, Fakhouri F, Grunfeld JP, (2000) Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol 11: 1767-1775.
57. Hall BK, Miyake T, (1992) The membranous skeleton: the role of cell condensations in vertebrate skeletogenesis. Anat Embryol (Berl) 186: 107-124.
58. Horster MF, Braun GS, Huber SM, (1999) Embryonic renal epithelia: induction, nephrogenesis, and cell differentiation. Physiol Rev 79: 1157-1191.
59. Stuart RO, Bush KT, Nigam SK, (2003) Changes in gene expression patterns in the ureteric bud and metanephric mesenchyme in models of kidney development. Kidney Int 64: 1997-2008.
60. Tulachan SS, Doi R, Hirai Y, Kawaguchi Y, Koizumi M, et al. (2006) Mesenchymal epimorphin is important for pancreatic duct morphogenesis. Dev Growth Differ 48: 65-72.
61. Hick AC, van Eyll JM, Cordi S, Forez C, Passante L, et al. (2009) Mechanism of primitive duct formation in the pancreas and submandibular glands: a role for SDF-1. BMC Dev Biol 9: 66.
62. Wescott MP, Rovira M, Reichert M, von Burstin J, Means A, et al. (2009) Pancreatic ductal morphogenesis and the Pdx1 homeodomain transcription factor. Mol Biol Cell 20: 4838-4844.
63. Torra R, Nicolau C, Badenas C, Navarro S, Perez L, et al. (1997) Ultrasonographic study of pancreatic cysts in autosomal dominant polycystic kidney disease. Clin Nephrol 47: 19-22.
64. Malka D, Hammel P, Vilgrain V, Flejou JF, Belghiti J, et al. (1998) Chronic obstructive pancreatitis due to a pancreatic cyst in a patient with autosomal dominant polycystic kidney disease. Gut 42: 131-134.
65. Liu Y, (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12.
66. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, et al. (2002) Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350.
67. Okada H, Ban S, Nagao S, Takahashi H, Suzuki H, et al. (2000) Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int 58: 587-597.
68. Togawa H, Nakanishi K, Mukaiyama H, Hama T, Shima Y, et al. (2011) Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease. Am J Physiol Renal Physiol 300: F511-520.
69. Chea SW, Lee KB, (2009) TGF-beta mediated epithelial-mesenchymal transition in autosomal dominant polycystic kidney disease. Yonsei Med J 50: 105-111.
70. Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, et al. (1992) Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 42: 1259-1265.
71. Xiao Z, Awad HA, Liu S, Mahlios J, Zhang S, et al. (2005) Selective Runx2-II deficiency leads to low-turnover osteopenia in adult mice. Dev Biol 283: 345-356.
72. Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, et al (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751-764.
73. Xiao Y, Lv X, Cao G, Bian G, Duan J, et al. (2009) Overexpression of Trpp5 contributes to cell proliferation and apoptosis probably through involving calcium homeostasis. Mol Cell Biochem.
74. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS, (2001) The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 16: 1754-1764.